Overview
Pharmaceutical

Immuno-Biological Laboratories Co.,Ltd.

Immuno-Biological Laboratories Co., Ltd. (IBL) develops, manufactures, and sells antibody-based research reagents, ELISA measurement kits, and in vitro diagnostic (IVD) products targeting life science researchers, pharmaceutical companies, and clinical laboratories. The company also operates a specialized lipoprotein profiling service (LipoSEARCH®) using patented GP-HPLC technology for clinical and basic research, as well as a transgenic silkworm (TG silkworm) contract manufacturing service for recombinant proteins and human-type collagen. Additional activities include antibody drug discovery (SFTS, GIST) for out-licensing and a cosmetics subsidiary utilizing its proprietary human-type collagen ingredient NeoSilk®.

Market Cap
¥9.34B
US$59.6M
EV
¥8.35B
US$53.2M
Stock¥1,003▲+0.50%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
23.0
x
LTM EV/EBIT
24.3
x
LTM PER
25.3
x
LTM PBR
4.9
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▲+87.2%pt
10012345
Oct 24, 25 – Oct 23, 26StockTOPIX
1Nov 17, 25Initial surge on US patent approval
2Nov 19, 25Rally on US patent approval news
3Nov 25, 25Daily surge on patent approval
4Nov 26, 25Consecutive limit-up on US patent news
5Nov 27, 25Speculative surge continues on US patent
MC → EV Bridge
9.34BUS$59.6MMarket Cap0.17BUS$1.10M+ Debt0.91BUS$5.79M− Cash0.26BUS$1.65M− Inv. Sec.8.35BUS$53.2MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.65US$4.13M'22/30.79US$5.06M'23/30.82US$5.20M'24/30.97US$6.18M'25/31.00US$6.40M'26/3
EBITDA 5Y (¥B)
0.11US$0.68M'24/30.22US$1.43M'25/30.30US$1.91M'26/3
Net Income 5Y (¥B)
-0.26-US$1.65M'22/3-0.29-US$1.84M'23/30.19US$1.19M'24/30.25US$1.59M'25/30.33US$2.10M'26/3
Capital Structure
92%
EquityD/E 0.09xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
0.91US$5.79M0.23US$1.49M'22/30.71US$4.52M0.23US$1.50M'23/30.83US$5.29M0.24US$1.50M'24/30.92US$5.87M0.20US$1.30M'25/31.16US$7.39M0.18US$1.13M'26/3
Shareholders
Top 10 hold 22.7%
1
Tsutomu KIYOFUJI
12.07%
2
Rakuten Securities, Inc. (Joint Account)
2.72%
3
TRANSGENIC GROUP INC.
1.72%
4
Shoko NAKAZAWA
1.09%
5
THE TOWA BANK,LTD.
1.07%
6
Katsuyuki DOI
1.02%
7
Takenori HAYASHI
0.89%
8
Rahim HAYASHI
0.75%
9
Nomura Securities Co., Ltd.
0.68%
10
NOMURA INTERNATIONAL PLC A/C JAPAN FLOW (Standing Proxy: Nomura Securities Co., Ltd.)
0.67%
Management
7 officers
Tsutomu KIYOFUJI
Representative Director, President
Sep 1964 Technical Staff, Department of Pathology, National Cancer Center Research Institute Apr 1975 Technical Staff, First Department of Pathology, Niigata University School of Medicine Sep 1978 Joined Japan Antibodies Research Institute, Ltd. Sep 1982 Established the Company; assumed office as Representative Director, President (current) Mar 2001 Established Gene Techno Science Co., Ltd.; assumed office as Representative Director Apr 2009 Assumed office as Representative Director, President and General Manager of Sales Division, the Company Aug 2009 Assumed office as Representative Director, Neo Silk Co., Ltd. Jun 2011 Assumed office as Director, Transgenic Inc. (currently Transgenic Group Inc.) (current) Jul 2013 Assumed office as Representative Director, Chairman, Skylight Biotech Inc. Feb 2021 Assumed office as Representative Director, President, AI Bio Inc. (current)
1944-09-29
Masato NAKAGAWA
Managing Director in Charge of Business Execution and General Manager, Business Group Administration Division
Apr 1983 Joined Wedds Co., Ltd. Apr 2003 General Manager, Accounting Department, Wedds Co., Ltd. Oct 2007 Joined the Company Apr 2008 General Manager, Finance and Accounting Department, the Company Jun 2008 Director, General Manager of Finance and Accounting Department and Head of President's Office, the Company Jun 2010 Director, General Manager of Finance and Accounting Department, the Company Jul 2013 Director, Skylight Biotech Inc. Jul 2013 Director, General Manager of Business Strategy Promotion Headquarters and Finance and Accounting Department, the Company Oct 2015 Corporate Auditor, Skylight Biotech Inc. Apr 2018 Director, General Manager of Business Group Administration Division and General Manager of Diagnostics and Reagents Business Division, the Company Jun 2019 Director, CURED Co., Ltd. Feb 2021 Corporate Auditor, AI Bio Inc. (current) Jun 2021 Managing Director in Charge of Business Execution and General Manager, Business Group Administration Division, the Company (current)
1962-08-05
Akiko ONODERA
Director, General Manager of Human Resources and General Affairs Department and Internal Audit Office Manager
Apr 1985 Joined the Company Apr 2001 General Manager, General Affairs and Accounting Department, the Company Jun 2001 Director, General Manager, General Affairs and Accounting Department, the Company Jun 2004 Director, General Manager of Administration Department, the Company Jun 2006 Director, General Manager of Human Resources and General Affairs Department, the Company Oct 2007 Director, General Manager of Administration Department, the Company Jun 2008 Executive Officer, General Manager of Human Resources and General Affairs Department and Internal Audit Office Manager, the Company Jun 2011 Director, General Manager of Human Resources and General Affairs Department and Internal Audit Office Manager, the Company (current) Jul 2013 Corporate Auditor, Skylight Biotech Inc. Nov 2013 Established Neo Silk Cosmetics Co., Ltd.; assumed office as Representative Director, President (current)
1961-05-15
Kenji FUKUNAGA
Director
Oct 1993 Joined Tohmatsu Audit Corporation (currently Deloitte Touche Tohmatsu LLC) Jun 1997 Registered as Certified Public Accountant Aug 2006 Opened Fukunaga Certified Public Accountant and Tax Accountant Office; Representative Jun 2009 Assumed office as Director, Transgenic Inc. (currently Transgenic Group Inc.) Jun 2010 Assumed office as Representative Director, President, Transgenic Inc. (currently Transgenic Group Inc.) (current) Jun 2011 Assumed office as Director, the Company (current) Apr 2013 Assumed office as Representative Director, President, Shinyaku Research Center Inc. (currently Transgenic Group Inc.) Oct 2013 Assumed office as Representative Director, President, Genetic Lab Co., Ltd. Nov 2017 Assumed office as Representative Director, President, TG Business Services Inc. (current) Mar 2018 Assumed office as Representative Director, President, Anpyo Center Co., Ltd. (currently Transgenic Inc.) Oct 2024 Assumed office as Representative Director, Chairman, Transgenic Inc. (current Director)
1969-08-13
Sadahiro OKAZUMI
Director, Full-time Audit and Supervisory Committee Member
May 1994 Registered as Judicial Scrivener May 1994 Opened Okazumi Judicial Scrivener Office Jul 2008 Registered as Administrative Scrivener May 2011 President, Gunma Association of Judicial Scriveners Jun 2013 Director, Japan Federation of Judicial Scrivener Associations Jan 2018 Opened Inoue & Okazumi Judicial Scrivener and Administrative Scrivener Office; assumed office as Co-Representative (current) Jun 2018 Assumed office as Corporate Auditor, the Company Jun 2026 Assumed office as Director, Audit and Supervisory Committee Member, the Company (current)
1967-06-02
Kazuyoshi KOJIMA
Director, Audit and Supervisory Committee Member
Dec 2010 Registered as Attorney-at-Law Dec 2010 Joined Takasaki Law Office Jun 2014 Joined Yuai Sogo Law Office, Attorney Corporation, Tokyo Office Jun 2019 Assumed office as Director, the Company Oct 2025 Assumed office as Representative, Yuai Sogo Law Office, Attorney Corporation (current) Apr 2026 Assumed office as Director, Audit and Supervisory Committee Member, Abalance Corporation (current) Jun 2026 Assumed office as Director, Audit and Supervisory Committee Member, the Company (current)
1983-01-02
Hirokazu KOJIMA
Director, Audit and Supervisory Committee Member
Oct 2000 Joined Ota Showa Century Audit Corporation (currently EY ShinNihon LLC) Jan 2019 Established Kojima Certified Public Accountant Office Apr 2019 Established Hirokazu Kojima Tax Accountant Office Jun 2021 Assumed office as Part-time Corporate Auditor, Yamada Manufacturing Co., Ltd. (current) Jun 2023 Assumed office as Non-executive Auditor, Gunma Credit Union (current) Jun 2026 Assumed office as Director, Audit and Supervisory Committee Member, the Company (current)
1974-08-13
Large Shareholding Reports
Tsutomu Seito
2026-09-30
13.48%→13.35%
Annual report (as of 2026-03-31): 12.07%
Tsutomu Seito
2026-09-30
12.88%→12.06%
Annual report (as of 2026-03-31): 12.07%
Tsutomu SEITO
2026-09-30
12.88%→12.88%
Annual report (as of 2026-03-31): 12.07%
Tsutomu SEITO
2026-09-30
12.06%→12.06%
Annual report (as of 2026-03-31): 12.07%
Tsutomu SEITO
2026-09-30
18.23%→15.32%
Annual report (as of 2026-03-31): 12.07%
Tsutomu Seito
2026-09-30
15.15%→15.15%
Annual report (as of 2026-03-31): 12.07%
Tsutomu Seito
2026-09-30
15.15%→13.48%
Annual report (as of 2026-03-31): 12.07%
Tsutomu Seito
2026-09-30
13.35%→12.88%
Annual report (as of 2026-03-31): 12.07%
Tsutomu SEITO
2026-09-30
12.06%→12.06%
Annual report (as of 2026-03-31): 12.07%
Tsutomu SEITO
2026-09-30
12.06%→12.06%
Annual report (as of 2026-03-31): 12.07%
Kiyofuji Tsutomu
2026-09-30
15.32%→15.15%
Annual report (as of 2026-03-31): 12.07%
Tsutomu SEITO
2026-09-30
13.48%→13.48%
Annual report (as of 2026-03-31): 12.07%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
EDINET
2026-09-30
Large Shareholding Report
TDnet
2026-08-07
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-26
Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2026-02-12
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2025-11-14
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-08
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-27
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-10
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-14
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-08
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-26
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINET
2024-02-14
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINET
2023-11-14
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-14
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-06-30
Annual Securities Report
Period: Apr 2022 – Mar 2023
EDINET
2023-02-13
Quarterly Securities Report
Period: Oct 2022 – Dec 2022
EDINET
2022-11-14
Quarterly Securities Report
EDINET
2022-08-15
Quarterly Securities Report
EDINET
2022-06-30
Annual Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →